Efficacy of neoadjuvant TCHP regimen in stage II-III HER2-positive breast cancer patients
Main Article Content
Abstract
The purpose of this study was to evaluate the total pathologic complete response (tpCR) rate and the safety profile of the neoadjuvant TCHP regimen (Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab) in patients diagnosed for HER2-positive breast cancer. This cross-sectional descriptive study was conducted on 97 patients with stage II-III HER2-positive breast cancer who completed six cycles of neoadjuvant TCHP at K Hospital between March 2021 and July 2025. The results show that the tpCR rate (ypT0/is ypN0) was 68%. The rates of pathologic complete response in tumors (ypT0/is) and axillary nodes (ypN0) were 74.2% and 79.4%, respectively. Multivariate analysis identified HER2-positive (3+) and hormone receptor status as independent prognostic factors associated with an increased likelihood of achieving tpCR. The incidence of grade 3-4 toxicities was low, primarily consisting of neutropenia (6.2%). No cardiotoxicity was recorded. The TCHP regimen demonstrates high therapeutic efficacy and is well-tolerated; therefore, it should be considered a preferred neoadjuvant treatment option for HER2-positive breast cancer.
Article Details
Keywords
HER2-positive breast cancer, neoadjuvant chemotherapy, TCHP, pathological complete response
References
2. Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. Jan 2018; 89: 27-35.
3. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. Jun 2016; 17(6): 791-800.
4. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. Feb 2 2005; 97(3): 188-194.
5. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. Jul 12 2014; 384(9938): 164-172.
6. van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. Dec 2018; 19(12): 1630-1640.
7. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017; 67(2): 93-99. doi:10.3322/caac.21388.
8. U.S. Department of health and human services. Common Terminology Criteria for Adverse Events(CTCAE). Published online 2017. https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf.
9. Dương Đoàn Yến Ngọc, Lê Thanh Vũ. Đánh giá kết quả hóa trị tân hỗ trợ kết hợp Trastuzumab điều trị bệnh nhân ung thư vú giai đoạn II-III tại Bệnh viện Ung bướu thành phố Hồ Chí Minh. Tạp chí Dược học Cần Thơ. 2024; (74): 106-111. doi:10.58490/ctump.2024i74.2559.
10. Đỗ Thị Thanh Mai, Nguyễn Tiến Quang, Phạm Văn Quân . Kết quả hoá trị trước phẫu thuật bệnh ung thư vú giai đoạn II, III bằng phác đồ TCH. Tạp chí Y học Việt Nam. 2022; 519(2). doi:10.51298/vmj.v519i2.3632.
11. Dinh Anh Tran, Le Huy Trinh, Tuan Anh Pham. Preliminary results of the 4AC-4THP neoadjuvant treatment for HER2 positive breast cancer. Tạp chí Nghiên cứu Y học. 2025; 196(11E17): 100-108. doi:10.52852/tcncyh.v196i11E17.3662.
12. Loibl S, Jackisch C, Schneeweiss A, et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol. Mar 1 2017; 28(3): 497-504.
13. Schettini F, Buono G, Cardalesi C, et al. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. Cancer Treatment Reviews. 2016/05/01/ 2016;46:20-26.